Bhaskar Dasgupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bhaskar Dasgupta has a total of 349 co-authors. Here are the top co-authors by number of shared publications:
- Kornelis S. M. van der Geest
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
8 shared publications Abdul Kayani
Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, Essex, UK
7 shared publicationsAlwin Sebastian
Rheumatology, Southend University Hospital, Mid and South Essex NHS Foundation Trust, Westcliff-on-sea, UK; School of Sport, Rehabilitation and Exercise science, University of Essex, Colchester, UK; Rheumatology, University Hospital Limerick, Dooradoyle, Ireland
7 shared publications- Christian Dejaco
Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical University Innsbruck, Bruneck, Italy
7 shared publications - Eric L. Matteson
Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA
6 shared publications Alessandro Tomelleri
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy
5 shared publications
Latest Publications
- Open Access
Anakinra versus intramuscular methylprednisolone acetate for gout flares in people with chronic kidney disease (ASGARD): a UK randomised multicentre, double-blind, double-dummy controlled feasibility study with economic, qualitative and safety assessment
Objectives Anakinra versus steroids for gout flares in people with renal disease (ASGARD) is a feasibility trial of undertaking a double-blind, double dummy randomised controlled trial of Anakinra versus intramuscular methylprednisolone acetate in people with gout and chronic kidney disease. Design A two-arm parallel group, double-blind, double-dummy, multicentre, randomised controlled trial. Setting ASGARD was undertaken in four centres in secondary care. Intervention Subcutaneous anakinra 100 mg daily for 5 days versus intramuscular methylprednisolone acetate 120 mg for gout flares in people with chronic kidney disease (estimated glomerular filtration rate (eGFR) 70% of eligible participants, Results The feasibility trial did not meet its overall criteria for success due to under-recruitment. It met procedural feasibility of recruiting ≥70% of eligible patients and ≤10% treatment crossovers or failure, 85% of participants completing 5 out of 7 participant-reported pain assessments (excluding four participants who did not receive allocated treatment). 21 participants (mean age 72 years, mean eGFR 44 mL/min/1.73 m2) were randomised; 17 received per protocol treatment. Mean reduction in pain after 7 days was 46.8 from baseline by 100 mm visual analogue score. Anakinra appeared to have a shorter time to pain reduction; however, this must be confirmed in a larger trial. Functional and quality of life assessments were highly completed. Health resource use was higher when assessed by health records. Qualitative feedback from participants alluded to high questionnaire burden and delays in receiving treatment. Conclusions We demonstrated the feasibility of conducting a definitive randomised controlled trial with insights from treatment effects, safety data, reconciliation of assessments, economic evaluation and participant experience. Improved case finding in the community, with streamlined processes during gout flare should be explored before recommendation for future trial can be made. Trial registration numbers EudraCT No. 2015-001787-19. NCT/ClinicalTrials.gov No. NCT02578394. WHO Universal Trials Reference No. U1111-1175-1977.
Open AccessAnakinra versus intramuscular methylprednisolone acetate for gout flares in people with chronic kidney disease (ASGARD): a UK randomised multicentre, double-blind, double-dummy controlled feasibility study with economic, qualitative and safety assessment
Objectives Anakinra versus steroids for gout flares in people with renal disease (ASGARD) is a feasibility trial of undertaking a double-blind, double dummy randomised controlled trial of Anakinra versus intramuscular methylprednisolone acetate in people with gout and chronic kidney disease. Design A two-arm parallel group, double-blind, double-dummy, multicentre, randomised controlled trial. Setting ASGARD was undertaken in four centres in secondary care. Intervention Subcutaneous anakinra 100 mg daily for 5 days versus intramuscular methylprednisolone acetate 120 mg for gout flares in people with chronic kidney disease (estimated glomerular filtration rate (eGFR) 70% of eligible participants, Results The feasibility trial did not meet its overall criteria for success due to under-recruitment. It met procedural feasibility of recruiting ≥70% of eligible patients and ≤10% treatment crossovers or failure, 85% of participants completing 5 out of 7 participant-reported pain assessments (excluding four participants who did not receive allocated treatment). 21 participants (mean age 72 years, mean eGFR 44 mL/min/1.73 m2) were randomised; 17 received per protocol treatment. Mean reduction in pain after 7 days was 46.8 from baseline by 100 mm visual analogue score. Anakinra appeared to have a shorter time to pain reduction; however, this must be confirmed in a larger trial. Functional and quality of life assessments were highly completed. Health resource use was higher when assessed by health records. Qualitative feedback from participants alluded to high questionnaire burden and delays in receiving treatment. Conclusions We demonstrated the feasibility of conducting a definitive randomised controlled trial with insights from treatment effects, safety data, reconciliation of assessments, economic evaluation and participant experience. Improved case finding in the community, with streamlined processes during gout flare should be explored before recommendation for future trial can be made. Trial registration numbers EudraCT No. 2015-001787-19. NCT/ClinicalTrials.gov No. NCT02578394. WHO Universal Trials Reference No. U1111-1175-1977.
- 21 April 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (4) , e70651
A Unified, Stratified Approach to the Large Vessel Vasculitis Spectrum and Imaging Implications
- 21 April 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (4) , e70651
A Unified, Stratified Approach to the Large Vessel Vasculitis Spectrum and Imaging Implications
- 11 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Should all polymyalgia rheumatica be referred to rheumatology? A call for unified stratified specialist care of the GCA-PMR spectrum
- 11 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Should all polymyalgia rheumatica be referred to rheumatology? A call for unified stratified specialist care of the GCA-PMR spectrum
- Open Access
Reliability of the OMERACT Giant cell arteritis Ultrasonography Score (OGUS): results of a patient-based exercise involving experts and non-experts in vascular ultrasonography
Objective To test the reliability of the Outcome Measures in Rheumatology Giant cell arteritis (GCA) Ultrasonography Score (OGUS) and other composite scores in a patient-based exercise involving experts and non-experts in vascular ultrasonography. Methods Six GCA patients were scanned twice (two rounds separated ≥3 hours) by 12 experts and 12 non-experts. Non-experts received 90 min of theoretical and 240 min of practical training between rounds 1 and 2. Ultrasonography was conducted on temporal arteries (common superficial, frontal and parietal branches) and axillary arteries bilaterally to calculate the OGUS, the Southend score and the Halo count. Inter-reader and intra-reader reliability were assessed by intraclass correlation coefficient (ICC). Results Mean age of GCA patients was 78±5.1 years, 2 (33.3%) were women, and all were in clinical remission. Expert inter-reader ICC of the OGUS was 0.60 in both rounds, 0.40 in round 1 and 0.51 in round 2 for the Southend score and 0.45 and 0.52, respectively, for the Halo count. Median ICCs for intra-reader reliability were 0.86, 0.73 and 0.65 for the OGUS, Southend score and Halo count, respectively. For non-experts, inter-reader ICCs in round 1 were 0.20 for the OGUS, 0.20 for a normalised Southend score (=score divided by available segments) and 0.35 for a normalised Halo count. After training, inter-reader reliability ICCs improved to 0.52, 0.29 and 0.54, respectively. Conclusion Inter-reader reliability was fair to moderate, and intra-reader reliability was good for OGUS, Southend score and Halo count among experts. Inter-reader reliability of non-experts in vascular ultrasonography improved after the training.
Open AccessReliability of the OMERACT Giant cell arteritis Ultrasonography Score (OGUS): results of a patient-based exercise involving experts and non-experts in vascular ultrasonography
Objective To test the reliability of the Outcome Measures in Rheumatology Giant cell arteritis (GCA) Ultrasonography Score (OGUS) and other composite scores in a patient-based exercise involving experts and non-experts in vascular ultrasonography. Methods Six GCA patients were scanned twice (two rounds separated ≥3 hours) by 12 experts and 12 non-experts. Non-experts received 90 min of theoretical and 240 min of practical training between rounds 1 and 2. Ultrasonography was conducted on temporal arteries (common superficial, frontal and parietal branches) and axillary arteries bilaterally to calculate the OGUS, the Southend score and the Halo count. Inter-reader and intra-reader reliability were assessed by intraclass correlation coefficient (ICC). Results Mean age of GCA patients was 78±5.1 years, 2 (33.3%) were women, and all were in clinical remission. Expert inter-reader ICC of the OGUS was 0.60 in both rounds, 0.40 in round 1 and 0.51 in round 2 for the Southend score and 0.45 and 0.52, respectively, for the Halo count. Median ICCs for intra-reader reliability were 0.86, 0.73 and 0.65 for the OGUS, Southend score and Halo count, respectively. For non-experts, inter-reader ICCs in round 1 were 0.20 for the OGUS, 0.20 for a normalised Southend score (=score divided by available segments) and 0.35 for a normalised Halo count. After training, inter-reader reliability ICCs improved to 0.52, 0.29 and 0.54, respectively. Conclusion Inter-reader reliability was fair to moderate, and intra-reader reliability was good for OGUS, Southend score and Halo count among experts. Inter-reader reliability of non-experts in vascular ultrasonography improved after the training.
- Top Cited Papers
- 12 June 2023
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 19 (7) , 446-459
Disease stratification in GCA and PMR: state of the art and future perspectives
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely related conditions characterized by systemic inflammation, a predominant IL-6 signature, an excellent response to glucocorticoids, a tendency to a chronic and relapsing course, and older age of the affected population. This Review highlights the emerging view that these diseases should be approached as linked conditions, unified under the term GCA–PMR spectrum disease (GPSD). In addition, GCA and PMR should be seen as non-monolithic conditions, with different risks of developing acute ischaemic complications and chronic vascular and tissue damage, different responses to available therapies and disparate relapse rates. A comprehensive stratification strategy for GPSD, guided by clinical findings, imaging and laboratory data, facilitates appropriate therapy and cost-effective use of health-economic resources. Patients presenting with predominant cranial symptoms and vascular involvement, who usually have a borderline elevation of inflammatory markers, are at an increased risk of sight loss in early disease but have fewer relapses in the long term, whereas the opposite is observed in patients with predominant large-vessel vasculitis. How the involvement of peripheral joint structures affects disease outcomes remains uncertain and understudied. In the future, all cases of new-onset GPSD should undergo early disease stratification, with their management adapted accordingly.
- 12 June 2023
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 19 (7) , 446-459
Top Cited PapersDisease stratification in GCA and PMR: state of the art and future perspectives
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely related conditions characterized by systemic inflammation, a predominant IL-6 signature, an excellent response to glucocorticoids, a tendency to a chronic and relapsing course, and older age of the affected population. This Review highlights the emerging view that these diseases should be approached as linked conditions, unified under the term GCA–PMR spectrum disease (GPSD). In addition, GCA and PMR should be seen as non-monolithic conditions, with different risks of developing acute ischaemic complications and chronic vascular and tissue damage, different responses to available therapies and disparate relapse rates. A comprehensive stratification strategy for GPSD, guided by clinical findings, imaging and laboratory data, facilitates appropriate therapy and cost-effective use of health-economic resources. Patients presenting with predominant cranial symptoms and vascular involvement, who usually have a borderline elevation of inflammatory markers, are at an increased risk of sight loss in early disease but have fewer relapses in the long term, whereas the opposite is observed in patients with predominant large-vessel vasculitis. How the involvement of peripheral joint structures affects disease outcomes remains uncertain and understudied. In the future, all cases of new-onset GPSD should undergo early disease stratification, with their management adapted accordingly.
- Top Cited PapersOpen Access
- 24 February 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (1) , 48-57
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
Objectives To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). Methods A systematic literature review was conducted to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of a T2T-based management approach in these diseases. Based on evidence and expert opinion, the task force (29 participants from 10 countries consisting of physicians, a healthcare professional and a patient) developed recommendations, with consensus obtained through voting. The final level of agreement was provided anonymously. Results Five overarching principles and six-specific recommendations were formulated. Management of GCA and PMR should be based on shared decisions between patient and physician recognising the need for urgent treatment of GCA to avoid ischaemic complications, and it should aim at maximising health-related quality of life in both diseases. The treatment targets are achievement and maintenance of remission, as well as prevention of tissue ischaemia and vascular damage. Comorbidities need to be considered when assessing disease activity and selecting treatment. Conclusion These are the first T2T recommendations for GCA and PMR. Treatment targets, as well as strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the gaps in evidence and the need for future research.
- 24 February 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (1) , 48-57
Top Cited PapersOpen AccessTreat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
Objectives To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). Methods A systematic literature review was conducted to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of a T2T-based management approach in these diseases. Based on evidence and expert opinion, the task force (29 participants from 10 countries consisting of physicians, a healthcare professional and a patient) developed recommendations, with consensus obtained through voting. The final level of agreement was provided anonymously. Results Five overarching principles and six-specific recommendations were formulated. Management of GCA and PMR should be based on shared decisions between patient and physician recognising the need for urgent treatment of GCA to avoid ischaemic complications, and it should aim at maximising health-related quality of life in both diseases. The treatment targets are achievement and maintenance of remission, as well as prevention of tissue ischaemia and vascular damage. Comorbidities need to be considered when assessing disease activity and selecting treatment. Conclusion These are the first T2T recommendations for GCA and PMR. Treatment targets, as well as strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the gaps in evidence and the need for future research.
- Open Access
- 1 February 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (2) , e43
Response to: ‘Correspondence on ‘Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia’’ by Evangelatos et al
- 1 February 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (2) , e43
Open AccessResponse to: ‘Correspondence on ‘Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia’’ by Evangelatos et al
- Open Access
- 1 September 2022
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 81 (9) , e176
Response to: ‘Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care’ by Molina Collada et al
- 1 September 2022
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 81 (9) , e176
Open AccessResponse to: ‘Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care’ by Molina Collada et al